Ali Dezhgir

Ali Dezhgir

Auto-generated profile, based on publicly available information

Ali Dezhgir

Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
HSHormoz Selahvarzi
Hormoz Selahvarzi
MKMilad Kamdideh
Milad Kamdideh
MVMehrnoosh Vahabi
Mehrnoosh Vahabi
ADAli Dezhgir
Ali Dezhgir
MHMassoud Houshmand
Massoud Houshmand
SSSoha Sadeghi
Soha Sadeghi
This study was carried out to investigate the relationship between common variants in two vitamin D pathway genes (VDR and CYP27B1) and vitamin D3 serum levels. In this study, serum vitamin D metabolite levels were measured in the blood samples of 200 patients with alopecia areata. Then, single nucleotide polymorphisms (SNPs) in VDR and CYP27B1 were analyzed using polymerase chain reaction (PCR)-sequencing. Sixty-three variations were observed in these genes (42 variations in CYP27B1 and 21 variations in VDR). A significant difference in Rs1544410 (odds ratio: 7, P < 0.0005) and rs4646536 (odds ratio: 4.043, P < 0.0005) variants was found between the patients and controls. The study showed the relationship between the two polymorphisms, Rs1544410 (odds ratio: 7, 95% CI, 1–8) and rs4646536 (odds ratio: 4.043, 95% CI, 3–14.038) on the genes VDR and CYP27B1, respectively, with increased risk of developing vitamin D3 insufficiency in the Iranian population. Therefore, SNPs in the VDR and CYP27B1 genes can be considered as prognostic biomarkers of the risk of developing vitamin D3 deficiency.

7 October 2017 in Edelweiss: Cancer Open Access
Verified
Journal Article
Open access
TTTayebe Talebzade
Tayebe Talebzade
FBFahimeh Baghbani-Arani
Fahimeh Baghbani-Arani
SSSoha Sadeghi
Soha Sadeghi
AHArvin Haghighatfard
Arvin Haghighatfard
NANiloofar Ahmadi
Niloofar Ahmadi
ADAli Dezhgir
Ali Dezhgir
Prostate cancer is the most prevalent and second cause of death from cancer in men worldwide. Immunotherapy is a new method for the treatment of several cancers that fights cancer cells by strengthening the immune system through some medications. While immunotherapy is a useful method for cancer treatment; its side effects still are not totally clarified. Numbers of prostate cancer patients which take immunotherapy are experiencing prostate inflammation and prostatitis after treatment period. Enterococcus faecalis is Gram-positive and catalase-negative cocci that are common in the intestines of humans and other animals and cause most enterococcal infections such as intestinal infections, prostatitis, gastroenteritis and endocarditic. Present study aimed to evaluate the mRNA level of virulence genes which are involved in Enterococcus faecalis pathogenesis in prostate cancer patients that treated by immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal surface protein (esp) genes were examined by Real time PCR in three groups of 68 male subjects. Group A normal subjects, group B prostate cancer patients before start treatment and group C prostate cancer patients after six months immunotherapy period. Results were showed significant (P<0.05) over expression of both genes (gelE and esp ) in group C against the group B. According to the results, it is reasonable that immunotherapy may have side effects such as increasing the pathogenicity risk of microflora in patients. Maybe these side effects could cause further infections after ending the immunotherapy of cancer. Antibiotic usage after or at the same time of immunotherapy period could prevent possible infections of microflora including E. faecalis.

1 January 2018 in Journal of Infection and Molecular Biology
Verified
Journal Article
Open access
SSSoha Sadeghi
Soha Sadeghi
TTTayebe Talebzade
Tayebe Talebzade
DADonya Altafi
Donya Altafi
HHHamed Hojatian
Hamed Hojatian
SRSahel Towfigh Rafiei
Sahel Towfigh Rafiei
AHArvin Haghighatfard
Arvin Haghighatfard
| Background: FDA has approved the immunotherapy for prostate cancer in 2010. Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response and is well known as specific and noninvasive method for cancer treatment; but side effects of this method are not clarified. Enterococci are Gram positive coccies, which are intestinal commensals and microflora of humans and other mammalians. Most enterococcal infections in human such as gastroenteritis, intestinal infections, prostatitis and endocarditic are causing by Enterococcus faecalis. Present study aimed to evaluate the side effects of immunotherapy on E. faecalis of microflora. Methods: mRNA level of 10 virulent genes (gelE, esp, asa1, aggA, cylA, cylB, cylM, Eep, efaA and enlA) which are involved in pathogenesis of E. faecalis, were examined in stool samples of two groups of men by quantitative real time PCR. Group A includes 359 prostate cancer patients and group B contains 360 normal family members of patients, which were lived with them at least for recent 12 months. Gene expression assessments in patient’s group were operated before start and after finishing a six weeks’ period of cancer vaccines immunotherapy. Results: Results were showed significant (P<0.05) over expression of 8 genes (gelE(P=0.001). asa1(P=0.001), esp (P=0.002), aggA(P=0.001), efaA(P=0.002), enlA(P=0.001), cylA(P=0.003) and cylB(P=0.003) in patients after treatment compared to before treatment. Also significant over expression of these 8 genes has been detected in patients after treatment in compare with normal related subjects. No significant alterations were observed in expression of virulence genes between normal subjects and patients before treatment. Conclusions: it seems that immunotherapy may carry side effects such as increasing the pathogenicity risk of microflora in treated patients. These side effects could cause further infections after ending the immunotherapy of cancer. Based on these results, antibiotic treatments after immunotherapy for prevention of potential infections could be recommended.